I'm just pointing out that Vasella was about the same age as Jimenez when he retired. I agree that the Vasella move was well telegraphed after a long tenure. Vasella was far and away my favorite CEO he set many of the directions that have been successful (focusing on biosimilars and more complex generic drugs rather than the commodity products that have had their margins gutted). He also fostered the model of developing drugs for rare genetic conditions and then looking for other indications that might have a similar genetic origins.
Under Jimenez there have been numerous actions that have resulted in questionable shareholder benefits (i.e, the Alcon acquisition. GSK asset swap, and numerous senior staff shuffling/defections.
I sold most of my NVS shares when it reached 100, so I have not followed it quite as closely.
Market Data 
Markets 
AI
